Cisplatin-based induction chemotherapy

Phase 3Small molecule

Cisplatin-based induction chemotherapy is one of 63 small molecule programs targeting Induction Chemotherapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Induction ChemotherapyRecruiting

Nasopharyngeal CarcinomaRecruiting

Induction ChemotherapyPhase 3

Recruiting

Nasopharyngeal CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

93 competitors in Nasopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Tuoyi

CCoherus Oncology, Inc.

Phase 3

21 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

20 3

Beyfortus

BeiGene

Phase 3

6 4

Taxotere

AAvyxa

Phase 3

15 5

Tuoyi

SSun Yat-sen University

Phase 3

11 6

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

10 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

6 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

6 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 10

Induction Phase1

Genmab

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Recruiting

Induction Chemotherapy

NCT06675214

Q4 2031

Phase 3Recruiting

Induction Chemotherapy

NCT06092957

Q2 2032

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT07328841

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT07328854

Clinical

Trials by Indication[1]

Induction Chemotherapy2 trials

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

Recruiting·SSun Yat-sen University·Phase 3·NCT06675214·586 enrolled

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

Recruiting·SSun Yat-sen University·Phase 3·NCT06092957·504 enrolled

Nasopharyngeal Carcinoma2 trials

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Recruiting·MMing-Yuan Chen·Phase 3·NCT07328841·456 enrolled

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Recruiting·MMing-Yuan Chen·Phase 3·NCT07328854·346 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Cisplatin-based induction chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cisplatin-based induction chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cisplatin-based induction chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

Cisplatin-based induction chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q4 2031

Q2 2032

Trials by Indication[1]

Induction Chemotherapy2 trials

Nasopharyngeal Carcinoma2 trials

References

Drug Info

Quick Facts

Related News